Teva Pharm Company Profile

✉ Email this page to a colleague

TEVA PHARM has three hundred and twenty-three approved drugs.

There are thirty-four US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and fifty-eight patent family members on TEVA PHARM drugs in thirty-seven countries and nine hundred and forty-five supplementary protection certificates in eighteen countries.

International Patents:	458
US Patents:	34
Tradenames:	269
Ingredients:	261
NDAs:	323
Patent Litigation for Teva Pharm:	See patent lawsuits for Teva Pharm
PTAB Cases with Teva Pharm as petitioner:	See PTAB cases with Teva Pharm as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	FLUVASTATIN SODIUM	fluvastatin sodium	CAPSULE;ORAL	078407-002	Jun 12, 2012	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017		RX	Yes	Yes	10,124,131*PED	⤷ Sign Up			Y	⤷ Sign Up
Teva Pharms Usa	LIOTHYRONINE SODIUM	liothyronine sodium	TABLET;ORAL	211510-002	Oct 26, 2018	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,871,646	⤷ Sign Up
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-003	Jan 27, 2017	6,446,627	⤷ Sign Up
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017	6,871,646	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14

Patent Number	Expiration Date
⤷ Sign Up	⤷ Sign Up

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613288	PA2011010	Lithuania	⤷ Sign Up	PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
0637297	SPC/GB01/041	United Kingdom	⤷ Sign Up	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
1613288	122011100047	Germany	⤷ Sign Up	PRODUCT NAME: FINGOLIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON; NAT. REGISTRATION NO/DATE: FIRST REGISTRATION: EU EU/1/11/677/001-004 20110317EU/1/11/677/001 EU/1/11/677/002 EU/1/11/677/003 EU/1/11/677/004 20110317
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.